# Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

> **NCT04460326** · PHASE3 · COMPLETED · sponsor: **Boston Medical Center** · enrollment: 137 (actual)

## Conditions studied

- Type 2 Diabetes Treated With Insulin

## Interventions

- **DRUG:** Insulin glargine
- **DRUG:** NovoLog
- **DRUG:** Insulin Fiasp
- **OTHER:** Standard carbohydrate diet

## Key facts

- **NCT ID:** NCT04460326
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2023-05-27
- **Final completion:** 2023-05-27
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2024-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460326, "Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04460326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*